Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCI-COG Pediatric MATCH - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations
NCT04195555Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2020
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of ivosidenib in solid tumor, lymphoma, histiocytic disorder, central nervous system tumor, sponsored by National Cancer Institute. Started Jul 2020; status: active, not recruiting.
02
Drugs
ivosidenib
03
Conditions
solid tumorlymphomahistiocytic disordercentral nervous system tumor
Beyond the preview
Go deeper on NCT04195555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04195555.